An update on the diagnosis and treatment of diabetic somatic and autonomic neuropathy [version 1; referees: 3 approved]

Shazli Azmi, Ioannis N. Petropoulos, Maryam Ferdousi, Georgios Ponirakis, Uazman Alam, Rayaz Malik

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes. It poses a significant challenge for clinicians as it is often diagnosed late when patients present with advanced consequences such as foot ulceration. Autonomic neuropathy (AN) is also a frequent and under-diagnosed complication unless it is overtly symptomatic. Both somatic and autonomic neuropathy are associated with increased mortality. Multiple clinical trials have failed because of limited efficacy in advanced disease, inadequate trial duration, lack of effective surrogate end-points and a lack of deterioration in the placebo arm in clinical trials of DPN. Multifactorial risk factor reduction, targeting glycaemia, blood pressure and lipids can reduce the progression of DPN and AN. Treatment of painful DPN reduces painful symptoms by about 50% at best, but there is limited efficacy with any single agent. This reflects the complex aetiology of painful DPN and argues for improved clinical phenotyping with the use of targeted therapy, taking into account co-morbid conditions such as anxiety, depression and sleep disturbance.

Original languageEnglish
Article number186
JournalF1000Research
Volume8
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Diabetic Neuropathies
Blood pressure
Peripheral Nervous System Diseases
Medical problems
Deterioration
Lipids
Clinical Trials
Therapeutics
Diabetes Complications
Risk Reduction Behavior
Foot
Sleep
Arm
Anxiety
Biomarkers
Placebos
Depression
Blood Pressure
Mortality

Keywords

  • Autonomic neuropathy
  • Diabetes mellitus
  • Peripheral neuropathy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

An update on the diagnosis and treatment of diabetic somatic and autonomic neuropathy [version 1; referees : 3 approved]. / Azmi, Shazli; Petropoulos, Ioannis N.; Ferdousi, Maryam; Ponirakis, Georgios; Alam, Uazman; Malik, Rayaz.

In: F1000Research, Vol. 8, 186, 01.01.2019.

Research output: Contribution to journalReview article

@article{da1233e7052c4dbb953b7580c5d9d454,
title = "An update on the diagnosis and treatment of diabetic somatic and autonomic neuropathy [version 1; referees: 3 approved]",
abstract = "Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes. It poses a significant challenge for clinicians as it is often diagnosed late when patients present with advanced consequences such as foot ulceration. Autonomic neuropathy (AN) is also a frequent and under-diagnosed complication unless it is overtly symptomatic. Both somatic and autonomic neuropathy are associated with increased mortality. Multiple clinical trials have failed because of limited efficacy in advanced disease, inadequate trial duration, lack of effective surrogate end-points and a lack of deterioration in the placebo arm in clinical trials of DPN. Multifactorial risk factor reduction, targeting glycaemia, blood pressure and lipids can reduce the progression of DPN and AN. Treatment of painful DPN reduces painful symptoms by about 50{\%} at best, but there is limited efficacy with any single agent. This reflects the complex aetiology of painful DPN and argues for improved clinical phenotyping with the use of targeted therapy, taking into account co-morbid conditions such as anxiety, depression and sleep disturbance.",
keywords = "Autonomic neuropathy, Diabetes mellitus, Peripheral neuropathy",
author = "Shazli Azmi and Petropoulos, {Ioannis N.} and Maryam Ferdousi and Georgios Ponirakis and Uazman Alam and Rayaz Malik",
year = "2019",
month = "1",
day = "1",
doi = "10.12688/f1000research.17118.1",
language = "English",
volume = "8",
journal = "F1000Research",
issn = "2046-1402",
publisher = "F1000 Research Ltd.",

}

TY - JOUR

T1 - An update on the diagnosis and treatment of diabetic somatic and autonomic neuropathy [version 1; referees

T2 - 3 approved]

AU - Azmi, Shazli

AU - Petropoulos, Ioannis N.

AU - Ferdousi, Maryam

AU - Ponirakis, Georgios

AU - Alam, Uazman

AU - Malik, Rayaz

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes. It poses a significant challenge for clinicians as it is often diagnosed late when patients present with advanced consequences such as foot ulceration. Autonomic neuropathy (AN) is also a frequent and under-diagnosed complication unless it is overtly symptomatic. Both somatic and autonomic neuropathy are associated with increased mortality. Multiple clinical trials have failed because of limited efficacy in advanced disease, inadequate trial duration, lack of effective surrogate end-points and a lack of deterioration in the placebo arm in clinical trials of DPN. Multifactorial risk factor reduction, targeting glycaemia, blood pressure and lipids can reduce the progression of DPN and AN. Treatment of painful DPN reduces painful symptoms by about 50% at best, but there is limited efficacy with any single agent. This reflects the complex aetiology of painful DPN and argues for improved clinical phenotyping with the use of targeted therapy, taking into account co-morbid conditions such as anxiety, depression and sleep disturbance.

AB - Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes. It poses a significant challenge for clinicians as it is often diagnosed late when patients present with advanced consequences such as foot ulceration. Autonomic neuropathy (AN) is also a frequent and under-diagnosed complication unless it is overtly symptomatic. Both somatic and autonomic neuropathy are associated with increased mortality. Multiple clinical trials have failed because of limited efficacy in advanced disease, inadequate trial duration, lack of effective surrogate end-points and a lack of deterioration in the placebo arm in clinical trials of DPN. Multifactorial risk factor reduction, targeting glycaemia, blood pressure and lipids can reduce the progression of DPN and AN. Treatment of painful DPN reduces painful symptoms by about 50% at best, but there is limited efficacy with any single agent. This reflects the complex aetiology of painful DPN and argues for improved clinical phenotyping with the use of targeted therapy, taking into account co-morbid conditions such as anxiety, depression and sleep disturbance.

KW - Autonomic neuropathy

KW - Diabetes mellitus

KW - Peripheral neuropathy

UR - http://www.scopus.com/inward/record.url?scp=85062405882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062405882&partnerID=8YFLogxK

U2 - 10.12688/f1000research.17118.1

DO - 10.12688/f1000research.17118.1

M3 - Review article

C2 - 30828432

AN - SCOPUS:85062405882

VL - 8

JO - F1000Research

JF - F1000Research

SN - 2046-1402

M1 - 186

ER -